PA-BOOMI
Boomi TM , the intelligent connectivity and automation leader, today claims two awards from Comparably , a leading workplace culture and corporate brand reputation platform, in their largest company category along with other 2022 honorees such as Microsoft, Adobe, IBM, Uber, and SADA. Honored with the Best CEOs for Diversity and Best Company for Career Growth awards – based on anonymous employee feedback from its more than 1,700 global employees – Boomi ranks among the top 50 largest companies for its commitments to, and achievements in, diversity and career advancement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220719005282/en/
“At Comparably we reward transparency in the workplace,” said Jason Nazar, co-founder and CEO at Comparably. “These awards empower employees to share personal insights about their company’s culture, rewarding and highlighting companies like Boomi, that do great work and set up their employees for success.”
Comparably selected the winners by evaluating over 15 million anonymous employee ratings across 70,000 of the largest companies. Boomi employees ranked their professional development opportunities, such as meaningful career advancement, mentorship, and valuable feedback, as high, which led to Boomi’s recognition among Best Companies for Career Growth. In awarding Best CEOs for Diversity to Boomi, Comparably evaluated ratings of Meredith from Boomi’s employees of color. The 2022 award for Meredith marks his second consecutive year receiving this important designation.
“As a category-leading, high growth, global software as a service (SaaS) company, Boomi strives to create and maintain a world-class employee experience,” said Shawn Maurice, Chief Human Resources Officer at Boomi. “We live by our motto of ‘hiring good humans’ and our unique, core values of Go Beyond, Play for Each Other, Create Awesome Things, Own It, and Build Trust. Boomi’s success ultimately lies in the hands of our team members, and we prioritize creating and nurturing an environment that supports their development and well-being, as well as encouraging them to be bold and find innovative, new solutions to challenges. These awards validate Boomi’s celebrated company culture as we continue to invest in our people.”
As the pioneer and category leader of cloud-native integration platform as a service (iPaaS), Boomi recently surpassed 20,000 customers , setting an industry record for largest customer base among iPaaS vendors. The company boasts a growing user community of over 100,000 members , a worldwide network of more than 800 partners , and one of the largest arrays of global system integrators (GSIs) in the iPaaS space. Boomi’s low-code platform helps organizations across all industries connect data applications, streamline workflows, and deliver more integrated customer experiences.
Boomi has been positioned as a Leader in the Gartner® Magic Quadrant™ for Enterprise Integration Platform as a Service (EiPaaS) for eight consecutive years .
The company recently received the Gold Globee® Award in the Platform as a Service (PaaS) category, and has garnered numerous awards for being an employer of choice, including a recent listing as one of Inc. Magazine’s Best Workplaces .
For a list of open positions on the Boomi team, visit the careers page on the Boomi website.
Additional Resources
- Explore the Boomiverse Community
- Follow Boomi on Twitter , LinkedIn , Facebook , and YouTube
Gartner Disclaimer:
Gartner, Magic Quadrant for Enterprise Integration Platform as a Service, Eric Thoo, Keith Guttridge, Bindi Bhullar, Shameen Pillai, Abhishek Singh, September 29, 2021
Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER and Magic Quadrant are registered trademarks and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Note: Boomi was recognized as Dell Boomi from 2014 to 2019.
About Boomi
Boomi instantly connects everyone to everything, anywhere with its cloud-native, unified, open, and intelligent platform. Boomi's integration platform as a service (iPaaS) is trusted by more than 20,000 customers globally for its speed, ease-of-use, and lower total cost of ownership. As the pioneer at fueling intelligent use of data, Boomi's vision is to make it quick and easy for customers and partners to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com
.
About Comparably
Comparably
is a leading workplace culture and corporate brand reputation platform with over 15 million anonymous employee ratings on 70,000 companies. With the most comprehensive data on large and SMB organizations in nearly 20 different workplace categories – based on gender, ethnicity, age, experience, industry, location, education – it is one of the most used SaaS platforms for employer branding and a trusted third party site for workplace culture and compensation. For more information on Comparably’s studies and annual Best Places to Work Awards, visit Comparably News
.
About Comparably Awards
Comparably Awards
is an annual series highlighting the best companies and CEOs in 16 different workplace culture categories throughout the year. Since launching in late 2017, the awards have always been based solely on sentiment feedback provided by current employees who anonymously rated their employers on Comparably.com during a 12- month look-back period. Employees can answer structured questions (in yes/no, true/false, 1-10 scale, and multiple choice formats) spanning 16 different workplace topics. Each answer is then given a numerical score and compared to companies of similar size. The final data set of winners are compiled from over 15 million ratings across 70,000 companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005282/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom